SAB Biotherapeutics

SABSW · NASDAQ

$0.0011−$0.0032 (−74.42%)TodayMarket closed · Oct 22, 4:00 PM ET

Prev close $0.0043

Latest news

Press releaseOct 13, 8:30 AM ETGlobe Newswire
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
Press releaseAug 6, 7:30 AM ETGlobe Newswire
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
Press releaseJul 30, 8:30 AM ETGlobe Newswire
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
Press releaseMay 12, 7:30 AM ETGlobe Newswire
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
Press releaseMay 5, 8:30 AM ETGlobe Newswire
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
Press releaseApr 22, 7:00 AM ETGlobe Newswire
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
Press releaseMar 19, 4:01 PM ETGlobe Newswire
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
Press releaseMar 17, 10:46 PM ETGlobe Newswire
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
Press releaseMar 17, 4:01 PM ETGlobe Newswire
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Press releaseMar 10, 7:31 AM ETGlobe Newswire
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
Press releaseMar 9, 5:16 PM ETGlobe Newswire
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
Press releaseJan 7, 8:00 AM ETGlobe Newswire
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
Press releaseNov 13, 5:00 PM ETGlobe Newswire
SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights
Press releaseJan 31, 7:00 AM ETGlobe Newswire
SAB BIO to Participate in Upcoming Investor Conferences
Press releaseNov 6, 5:05 PM ETGlobe Newswire
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
Press releaseOct 31, 7:00 AM ETGlobe Newswire
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
Press releaseSep 13, 7:00 AM ETGlobe Newswire
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
Press releaseAug 8, 5:51 PM ETGlobe Newswire
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

SAB BIO to Participate in Upcoming Investor Conferences

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates